A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer

Summary

Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well imatinib mesylate works in treating patients with refractory metastatic and/or unresectable stomach or gastroesophageal junction cancer.

Timeline

Start

2004-03

Primary completion

2010-03

Completion

2010-03

Drugs

Indications